<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Asthma. In: Pulmonary (acute &amp;amp; chronic)&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Asthma. In: Pulmonary (acute &amp; chronic). Encinitas (CA): Work Loss Data Institute; 2013 Oct 29. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Asthma. In: Pulmonary (acute &amp;amp; chronic). San Diego (CA): Work Loss Data Institute; 2009. p. 2-18.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Administration of psychologic test  (94.02); Asthma, unspecified type, with (acute) exacerbation  (493.92); Chronic obstructive asthma, unspecified  (493.20); Plethysmogram  (89.58)"/><FieldValue Value="MSH: Acute Disease ; Administration, Inhalation ; Adrenal Cortex Hormones ; Adrenergic beta-2 Receptor Agonists ; Adrenergic beta-Agonists ; Albuterol ; Androstadienes ; Anti-Asthmatic Agents ; Anti-Bacterial Agents ; Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Asthma ; Bronchodilator Agents ; Budesonide ; Cholinergic Antagonists ; Chronic Disease ; Drug Therapy, Combination ; Ethanolamines ; Immunotherapy ; Ipratropium ; Leukotriene Antagonists ; Levalbuterol ; Occupational Health Services ; Office Visits ; Patient Education as Topic ; Physical Therapy Modalities ; Plethysmography ; Prednisolone ; Prednisone ; Psychological Tests ; Rehabilitation ; Respiratory Function Tests ; Respiratory Therapy ; Return to Work ; Risk Reduction Behavior ; Skin Tests ; Spirometry ; Theophylline ; Tosyl Compounds ; Ubiquinone "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; Adrenergic beta-2 Receptor Agonists ; Adrenergic beta-Agonists ; Anti-Bacterial Agents ; Antibiotics ; Antibodies, Anti-Idiotypic ; Anticholinergic Agents ; Asthma ; Cholinergic Antagonists ; Chronic disease ; coenzyme Q10 ; Combination Drug Therapy ; Ethanolamines ; Exacerbation of asthma ; formoterol ; Hypersensitivity skin testing ; Immunotherapy ; Inhalation Drug Administration ; Leukotriene Antagonists ; Monoclonal Antibodies ; Patient education (procedure) ; Physical therapy ; Plain chest X-ray ; prednisolone ; Prednisone ; Psychological Tests (procedure) ; Pulmonary rehabilitation (procedure) ; Radiographic-therapeutic unit device ; Rehabilitation therapy ; Respiratory Function Tests ; Respiratory Therapy ; Spirometer (device) ; Theophylline ; Ubiquinone "/><FieldValue Value="PDQ: budesonide ; coenzyme Q10 ; physiotherapy ; prednisolone ; prednisone ; theophylline "/><FieldValue Value="SNOMEDCT_US: Acute asthma  (304527002); Acute disease  (2704003); Albuterol  (372897005); Albuterol  (91143003); Albuterol + ipratropium  (421685007); Antiasthmatic agent  (360253007); Antibacterial agent  (346325008); Antibacterial agent  (419241000); Antibiotic  (255631004); Anticholinergic agent  (14601000); Anticholinergic agent  (373246003); Asthma  (195967001); Asthma trigger finding  (397579009); Avoidance behavior  (284489004); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Bronchodilator  (353866001); Bronchodilator  (372580007); Budesonide  (108622005); Budesonide  (395726003); Budesonide + formoterol  (413717007); Chronic disease  (27624003); Coenzyme Q10  (412129003); Coenzyme Q10  (412130008); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Exacerbation of asthma  (281239006); Fit to return to work  (302120006); Fluticasone  (108632003); Fluticasone  (397192001); Fluticasone + salmeterol  (411106009); Formoterol  (386171009); Formoterol  (414289007); Grass pollen allergen  (410986002); Hypersensitivity skin testing  (164838003); Hypersensitivity skin testing  (268377001); Hypersensitivity skin testing  (53309004); Immunological therapy  (76334006); Inhaled drug administration  (243132000); Ipratropium  (108624006); Ipratropium  (372518007); Leukotriene receptor inhibitor  (108616001); Leukotriene receptor inhibitor  (372517002); Levalbuterol  (116090007); Levalbuterol  (398965008); Measurement of respiratory function  (23426006); Monoclonal antibody  (49616005); Montelukast  (320883008); Montelukast  (373728005); Occupational health service  (2471000175109); Occupational health service  (310064001); Omalizumab  (406442003); Omalizumab  (406443008); Patient education  (311401005); Physical therapy procedure  (91251008); Pirbuterol  (108611006); Pirbuterol  (372516006); Plain chest X-ray  (399208008); Plethysmograph  (706495008); Plethysmography  (20552003); Prednisolone  (116601002); Prednisolone  (52388000); Prednisone  (10312003); Prednisone  (116602009); Psychologic test  (1999007); Psychological assessment  (405783006); Psychological assessment  (45392008); Pulmonary rehabilitation  (15081005); Radiographic-therapeutic unit  (10850003); Rehabilitation therapy  (52052004); Respiratory therapy  (53950000); Respiratory tract rehabilitation procedure  (108228000); Returned to work  (266962006); Salmeterol  (108605008); Salmeterol  (372515005); Spirometer  (303501006); Spirometry  (127783003); Theophylline  (372810006); Theophylline  (66493003); Zafirlukast  (108614003); Zafirlukast  (386880006)"/><FieldValue Value="UMD: Inhalers, Aerosol  (12-128); Plethysmographs  (13-056); Radiographic Systems  (18-429); Radiotherapy Systems  (13-279); Spirometers  (13-674)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm416408.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;September 26, 2014 &amp;ndash; Xolair (omalizumab)&lt;/a&gt;: A U.S. Food and Drug Administration (FDA) review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair. As a result, FDA has added information about these potential risks to the drug label. &lt;/li&gt;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exacerbation of asthma &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Pharmacology" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Health Plans" /><FieldValue Value="Hospitals" /><FieldValue Value="Managed Care Organizations" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /><FieldValue Value="Utilization Management" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To offer evidence-based step-by-step decision protocols for the assessment and treatment of asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Workers with asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following interventions/procedures were considered and recommended as indicated in the original guideline document:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Anticholinergic (inhaled) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoidance activities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Causality determination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coenzyme Q10 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Corticosteroids (inhaled) (budesonide, fluticasone) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Corticosteroids (oral) (prednisone, prednisolone) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combination long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICS) (Advair&amp;reg; [salmeterol/fluticasone]; Combivent&amp;reg; [albuterol/ipratropium]; Symbicort&amp;reg; [formoterol/budesonide]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Grass pollen allergoid immunotherapy (Grazax) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled LABAs (formoterol, salmeterol) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled short-acting beta-agonists (SABAs) (albuterol, levalbuterol, pirbuterol) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Leukotriene receptor antagonists (LTRAs) (montelukast, zafirlukast) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Office visits &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Omalizumab (anti-immunoglobulin-E) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychological evaluation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary function testing (spirometry, plethysmography) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary rehabilitation program &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radiography (diagnostic) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reslizumab &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Respiratory muscle training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Return to work &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Skin tests for allergies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Theophyllines &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The following interventions/procedures are under study and are not specifically recommended:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bronchodilators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mepolizumab and other immunomodulators &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The following interventions were considered but are not currently recommended:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Proton-pump inhibitors (PPIs) as a treatment for asthma or chronic cough&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relief of symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise tolerance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Disease exacerbation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Length of hospital stay &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Disability duration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Loss Data Institute (WLDI) conducted a comprehensive medical literature review (now ongoing) with preference given to high quality systematic reviews, meta-analyses, and clinical trials published since 1993, plus existing nationally recognized treatment guidelines from the leading specialty societies. WLDI primarily searched MEDLINE and the Cochrane Library. In addition, WLDI also reviewed other relevant treatment guidelines, including those in the National Guideline Clearinghouse, as well as state guidelines and proprietary guidelines maintained in the WLDI guideline library. These guidelines were also used to suggest references or search terms that may otherwise have been missed. In addition, WLDI also searched other databases, including MD Consult, eMedicine, CINAHL, and conference proceedings in occupational health (i.e., American College of Occupational and Environmental Medicine [ACOEM]) and disability evaluation (i.e., American Academy of Disability Evaluating Physicians [AADEP], American Board of Independent Medical Examiners [ABIME]). Search terms and questions were diagnosis, treatment, symptom, sign, and/or body-part driven, generated based on new or previously indexed existing evidence, treatment parameters and experience.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In searching the medical literature, answers to the following questions were sought: (1) If the diagnostic criteria for a given condition have changed since 1993, what are the new diagnostic criteria? (2) What occupational exposures or activities are associated causally with the condition? (3) What are the most effective methods and approaches for the early identification and diagnosis of the condition? (4) What historical information, clinical examination findings or ancillary test results (such as laboratory or x-ray studies) are of value in determining whether a condition was caused by the patient's employment? (5) What are the most effective methods and approaches for treating the condition? (6) What are the specific indications, if any, for surgery as a means of treating the condition? (7) What are the relative benefits and harms of the various surgical and non-surgical interventions that may be used to treat the condition? (8) What is the relationship, if any, between a patient's age, gender, socioeconomic status and/or racial or ethnic grouping and specific treatment outcomes for the condition? (9) What instruments or techniques, if any, accurately assess functional limitations in an individual with the condition? (10) What is the natural history of the disorder? (11) Prior to treatment, what are the typical functional limitations for an individual with the condition? (12) Following treatment, what are the typical functional limitations for an individual with the condition? (13) Following treatment, what are the most cost-effective methods for preventing the recurrence of signs or symptoms of the condition, and how does this vary depending upon patient-specific matters such as underlying health problems?&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Criteria for Selecting the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Preference was given to evidence that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial &amp;ndash; randomized or controlled, or (4) The article reports a cohort study, whether prospective or retrospective, or (5) The article reports a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;More information about the selection of evidence is available in &quot;Appendix B. &lt;em&gt;ODG Treatment in Workers' Comp&lt;/em&gt;. Methodology description using the AGREE instrument&quot; (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Ranking by Type of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Systematic Review/Meta-Analysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled Trial&amp;mdash;Randomized (RCT) or Controlled &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cohort Study&amp;mdash;Prospective or Retrospective &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Case Control Series &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Unstructured Review &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nationally Recognized Treatment Guideline (from &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;www.guideline.gov&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;State Treatment Guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other Treatment Guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Textbook &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conference Proceedings/Presentation Slides &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ranking by Quality within Type of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;High Quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medium Quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low Quality &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Loss Data Institute (WLDI) reviewed each article that was relevant to answering the question at issue, with priority given to those that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial &amp;ndash; randomized or controlled, or (4) The article reported a cohort study, whether prospective or retrospective, or (5) The article reported a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Especially when articles on a specific topic that met the above criteria were limited in number and quality, WLDI also reviewed other articles that did not meet the above criteria, but all evidence was ranked alphanumerically (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field) so that the quality of evidence could be clearly determined when making decisions about what to recommend in the Guidelines. Articles with a Ranking by Type of Evidence of Case Reports and Case Series were not used in the evidence base for the Guidelines. These articles were not included because of their low quality (i.e., they tend to be anecdotal descriptions of what happened with no attempt to control for variables that might affect outcome). Not all the evidence provided by WLDI was eventually listed in the bibliography of the published Guidelines. Only the higher quality references were listed. The criteria for inclusion was a final ranking of 1a to 4b (the original inclusion criteria suggested the methodology subgroup), or if the Ranking by Type of Evidence was 5 to 10, the quality ranking should be an &quot;a.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Prior to publication, select organizations and individuals making up a cross-section of medical specialties and typical end-users externally reviewed the guideline. Complimentary review access is also made available to all major medical specialty groups as well as other stakeholders.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC)&lt;/strong&gt;: This guideline is a part of a larger document, &lt;em&gt;Pulmonary (Acute &amp;amp; Chronic)&lt;/em&gt;, which, in addition to &quot;Asthma,&quot; includes the following chapters:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=47575&quot; title=&quot;Guideline #10110&quot;&gt;Chronic obstructive pulmonary disease (COPD)&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=47576&quot; title=&quot;Guideline #10111&quot;&gt;Cough&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=47587&quot; title=&quot;Guideline #10122&quot;&gt;Lung cancer and cancer of the pleura&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;/content.aspx?id=47584&quot; title=&quot;Guideline #10119&quot;&gt;Interstitial lung disease&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial evaluation starts with making a presumptive diagnosis of asthma. This presumptive diagnosis is based on a combination of the history, the physical examination, and pulmonary function testing.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Historical clues to the presence of asthma include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A history of any of the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Cough (especially if worse at night) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recurrent wheeze &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recurrent difficulty in breathing &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recurrent chest tightness &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptoms occur or worsen in the presence of:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Exercise &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Viral infection &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Inhalant allergens &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Irritants &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Changes in the weather &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical or emotional stress &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Menstrual cycles &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptoms that occur or worsen at night, awakening the patient &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Physical examination features that suggest asthma include signs of inflammatory disease of the upper airway, wheezing, signs of respiratory distress including diminished breath sounds, and signs of atopic skin disease. However, it should be noted that asthma is an episodic disease and, depending on severity, an individual may have no physical examination findings on a given day. Thus, a normal examination does not rule out a diagnosis of asthma.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Pulmonary function testing relies on the simple spirometry and/or peak flow meters. With spirometric testing, the goal is to demonstrate hyper-reactive airway physiology by:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;An exaggerated response to bronchodilators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An exaggerated response to bronchoconstrictors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An exaggerated response to bronchoprovocative agents (other than medications causing constriction) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Variability in serial testing correlated with symptoms, medications, and examination findings &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The goal of therapy is to return the individual to as near a baseline as normal with the least use of medication as possible.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The first visit should focus on the history, including the family history of asthma, allergic disease, or upper airway conditions. It should also focus on elements found in the differential of this condition such as other diseases causing shortness of breath such as COPD, congestive heart failure or other types of heart disease, anemia, and other pulmonary conditions and diseases causing wheezing such as COPD, acute respiratory infections, and airway tumors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After completion of the history and physical examinations, determine if further testing is needed to confirm asthma or if a trial of empiric therapy is warranted based on a presumptive diagnosis. If further testing is needed to establish a diagnosis, consider serial peak flow monitoring or a spirometry before and after the use of a bronchodilator.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The end result of the initial visit will be one of three scenarios:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A presumptive diagnosis of asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A good possibility of asthma but one that requires further confirmation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A working differential list that includes asthma as one of the potential diagnoses&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Presumptive Diagnosis&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Asthma (see the original guideline document for International Classification of Diseases, Ninth Revision [ICD-9] codes for this and other diagnoses) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Extrinsic asthma &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Intrinsic asthma &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Chronic obstructive asthma &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Other forms of asthma&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Exercise induced bronchospasm (EIB) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cough variant asthma &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Asthma, unspecified &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;For the first scenario, the treatment begins with the first visit. The Expert Panel Report 3 (EPR3) published by the National Heart, Lung, and Blood Institute (NHLBI) (reprinted below with the age groups 0&amp;ndash;4 and 5&amp;ndash;11 omitted) identified four components needed to care for these patients:&lt;/p&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Patient assessment and monitoring &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Patient education &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Attaining control over environmental factors and controlling co-morbid conditions &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Treatment&#xD;&#xA;            &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;                &lt;li&gt;In order to achieve the goals outlined above, assess and monitor asthma severity and asthma control. This assessment of severity is used to initiate control, using the stepwise approach found below. Use Step 1 for individuals classified as having intermittent asthma (when well-controlled), Step 2 for mild persistent asthma, Step 3 or 4 for moderate persistent asthma, and Step 5 or 6 for severe persistent asthma. Additionally, precipitating causes should be minimized and/or treated (for example, eliminating as much as possible airway irritants in the home or workplace, the use of immunotherapy for atopic asthmatics, and the treatment of gastroesophageal reflux disease [GERD] in patients who have this condition as a trigger for their asthma.) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The educational component can be provided in several different formats:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Face-to-face discussion either by physician or by surrogate such as office staff, respiratory therapy department at hospital, or others &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Video presentations (usually pre-recorded from either external sources but can also be &quot;home-made&quot; &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Written material &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;p&gt;In any case, the educational material is recommended to be delivered at a level suitable for the individual. It should be presented on an on-going basis, although the content should vary for subsequent office visits. Patient education should be part of each office visit. Lastly, an asthma self-management program should be taught to each patient. Methods of understanding should be developed for each patient and the physician should review the patient's understanding of the self-management program. The goal is to make the patient an active partner in the treatment program. The NHLBI document has sample education components, lists of educational resources, and a sample of a home self-management action plan and is available at&lt;a href=&quot;http://www.nhlbi.nih.gov/&quot; title=&quot;NHLBI Web site&quot; target=&quot;_blank&quot;&gt; www.nhlbi.nih.gov&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;                &lt;li&gt;It is the physician's role to mitigate, as much as possible, co-morbid conditions by working in concert with referring/consulting physicians. It is the patient's role to identify and help control environmental factors. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The treatment program is detailed below in a step chart. The treatment program, as defined and suggested by the EPR3, depends on the classification of the patient's degree of asthma. The goals of treatment, as presented by the EPR3 are: &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Goal of Treatment: Control of Asthma&quot;&gt;&#xD;&#xA;            &lt;thead&gt;&#xD;&#xA;                &lt;tr&gt;&#xD;&#xA;                    &lt;th valign=&quot;top&quot;&gt;Goal of Treatment: Control of Asthma&lt;/th&gt;&#xD;&#xA;                &lt;/tr&gt;&#xD;&#xA;            &lt;/thead&gt;&#xD;&#xA;            &lt;tbody&gt;&#xD;&#xA;                &lt;tr&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Reduce Impairment&lt;/strong&gt;&#xD;&#xA;                    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                        &lt;li&gt;Prevent chronic and troublesome symptoms (e.g., coughing or breathlessness in the daytime, in the night, or after exertion). &lt;/li&gt;&#xD;&#xA;                        &lt;li&gt;Require infrequent use (&amp;le;2 days a week) of inhaled short-acting beta-adrenergics (SABAs) for quick relief of symptoms (not including prevention of exercise-induced bronchospasm [EIB]). &lt;/li&gt;&#xD;&#xA;                        &lt;li&gt;Maintain (near) normal pulmonary function. &lt;/li&gt;&#xD;&#xA;                        &lt;li&gt;Meet patients' and families' expectations of and satisfaction with asthma care. &lt;/li&gt;&#xD;&#xA;                    &lt;/ul&gt;&#xD;&#xA;                    &lt;br /&gt;&#xD;&#xA;                    &lt;strong&gt;Reduce Risk&lt;/strong&gt;&#xD;&#xA;                    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                        &lt;li&gt;Prevent recurrent exacerbations of asthma and minimize the need for emergency department (ED) visits or hospitalizations. &lt;/li&gt;&#xD;&#xA;                        &lt;li&gt;Prevent loss of lung function; for children, prevent reduced lung growth. &lt;/li&gt;&#xD;&#xA;                        &lt;li&gt;Provide optimal pharmacotherapy with minimal or no adverse effects of therapy. &lt;/li&gt;&#xD;&#xA;                    &lt;/ul&gt;&#xD;&#xA;                    &lt;/td&gt;&#xD;&#xA;                &lt;/tr&gt;&#xD;&#xA;            &lt;/tbody&gt;&#xD;&#xA;        &lt;/table&gt;&#xD;&#xA;        &lt;p&gt;Treatment must be individualized for each patient, controlling for the following variables:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Therapeutic efficacy &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Side effects and/or potential &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Compliance capability &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Cost &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;And should be at the least amount to maintain control. The maintenance of control over the patient's asthma is determined by any/all of the following:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;History of control &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Pulmonary function testing &amp;ndash; either by serial spirometries performed at the office visit or peak flow diaries &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;When the diagnosis is unclear, perform the following tests:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Spirometry with and without bronchodilators, or &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Bronchoprovocative testing (usually with methacholine or histamine) &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;        &lt;li&gt;Consider referral to a specialist if the symptoms are atypical, if additional testing should be performed, or if there are more problems with the differential diagnosis. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summary of Recommended Key Clinical Activities for the Diagnosis and Management of Asthma&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Summary of Recommended Key Clinical Activities for the Diagnosis and Management of Asthma&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Clinical Issues&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Key Clinical Activities&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Action Steps&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Four Components of Care&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;Assessment and Monitoring&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess asthma severity to initiate therapy.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Use asthma control chart, assessing both domains of impairment and risk to determine if therapy should be maintained or adjusted (step up if necessary, step down if possible)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess asthma control to monitor and adjust therapy.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Use asthma control chart, assessing both domains of impairment and risk to determine if therapy should be maintained or adjusted (step up if necessary, step down if possible). &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Use multiple measures of impairment and risk; different measures assess different manifestations of asthma; they may not correlate with each other; and they may respond differently to therapy. Obtain lung function measures by spirometry at least every 1-2 years, more frequently for not well-controlled asthma. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Schedule follow-up care.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Asthma is highly variable over time, and periodic monitoring is essential. In general, consider scheduling patients at 2- to-8-week intervals while gaining control; at 1- to 6-month intervals, depending on step of care required or duration of control, to monitor if sufficient control is maintained; at 3-month intervals if a step down in therapy is anticipated. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Assess asthma control, medication technique, written asthma action plan, patient adherence and concerns at every visit.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;Education&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide self-management education.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Teach and reinforce:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Self-monitoring to assess level of asthma control and signs of worsening asthma (either symptom or peak flow monitoring shows similar benefits for most patients). Peak flow monitoring may be particularly helpful for patients who have difficulty perceiving symptoms, a history of severe exacerbations, or moderate or severe asthma. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Using written asthma action plan (review differences between long-term control and quick-relief medication). &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Taking medication correctly (inhaler technique and use of devices). &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Avoiding environmental factors that worsen asthma. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Tailor education to literacy level of patient. Appreciate the potential role of a patient's cultural beliefs and practices in asthma management. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Develop a written asthma action plan in partnership with patient.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Agree on treatment goals and address patient concerns.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Integrate education into all points of care where health professionals interact with patients.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide instructions for (1) daily management (long-term control medication, if appropriate, and environmental control measures) and (2) managing worsening asthma (how to adjust medication, and know when to seek medical care). &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Involve all members of the health care team in providing and reinforcing education, including physicians, nurses, pharmacists, respiratory therapists, and asthma educators. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Encourage education at all points of care: clinics (offering separate self-management education programs as well as incorporating education into every patient visit), Emergency Departments and hospitals, pharmacies, schools and other community settings, and patients' homes. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Use a variety of educational strategies and methods.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Control Environmental Factors and Comorbid Conditions&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommend measures to control exposures to allergens and pollutants or irritants that make asthma worse.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Determine exposures, history of symptoms in presence of exposures, and sensitivities (in patients who have persistent asthma, use skin or in vitro testing to assess sensitivity to perennial indoor allergens). &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Advise patients on ways to reduce exposure to allergens, pollutants, or irritants to which the patient is sensitive. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Multifaceted approaches are beneficial; single steps alone are generally ineffective. Advise all patients and pregnant women to avoid exposure to tobacco smoke. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Consider allergen immunotherapy, by specifically trained personnel, for patients who have persistent asthma and when there is clear evidence of a relationship between symptoms and exposure to an allergen to which the patient is sensitive. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Treat co-morbid conditions.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider especially: allergic bronchopulmonary aspergillosis, gastroesophageal reflux, obesity, obstructive sleep apnea, rhinitis and sinusitis, and stress or depression. Recognition and treatment of these conditions may improve asthma control. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Consider inactivated influenza vaccine for all patients over 6 months of age.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Medications&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Select medication and delivery devices to meet patient's needs and circumstances.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Use stepwise approach (see below) to identify appropriate treatment options. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Inhaled corticosteroids (ICSs) are the most effective long-term control therapy. When choosing among treatment options, consider domain of relevance to the patient (impairment, risk or both), patient's history of response to the medication, and patient's willingness and ability to use the medication. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Stepwise Approach&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;6&quot;&gt;General Principles for All Age Groups&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Incorporate four components of care.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Include medications, patient education, environmental control measures, and management of co-morbidities at each step. Monitor asthma control regularly (see above, assessment and monitoring).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Initiate therapy based on asthma severity.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;For patients not taking long-term control therapy, select treatment step based on severity. (See figures on stepwise approach for different age groups.) Patients who have persistent asthma require daily long-term control medication.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Adjust therapy based on asthma control.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Once therapy is initiated, monitor the level of asthma control and adjust therapy accordingly; step up if necessary and step down if possible to identify the minimum amount of medication required to maintain asthma control. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Refer to an asthma specialist for consultation or co-management if there are difficulties achieving or maintaining control; step 4 care or higher is required (step 3 care or higher for children 0-4 years of age); immunotherapy or omalizumab is considered; or additional testing is indicated or if the patient required 2 bursts of oral systemic corticosteroids in the past year or a hospitalization. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Promote physical activity.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Treat EIB. Step up daily therapy if the patient has poor endurance or symptoms during normal daily activities.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess possible benefit of treatment in older patients&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Establish reversibility with a short course of oral systemic corticosteroids.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Adjust medications to address coexisting medical conditions common among older patients.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider, for example, calcium and vitamin D supplements for patients who take ICS and have risk factors for osteoporosis; increased sensitivity to side effects of bronchodilators with increasing age; increased drug interactions with theophylline, medications for arthritis (nonsteroidal anti-inflammatory drugs [NSAIDs]), hypertension, or glaucoma (beta-blockers) may exacerbate asthma. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Exercise-induced Bronchospasm (EIB)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Prevent EIB&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Treatment strategies to prevent EIB include:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Long-term control therapy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Pretreatment before exercise with short-acting beta-adrenergics (SABAs), leukotriene receptor antagonists (LTRAs), cromolyn or nedocromil; frequent or chronic use of long-acting beta-agonist (LABA) for pretreatment is discouraged, as it may disguise poorly controlled persistent asthma &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Warm-up period or a mask or scarf over the mouth for cold-induced EIB &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Ages 12 and Older&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Involve youths in developing written asthma action plan.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Address youth's concerns, preferences, and school schedule in selecting treatment. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Encourage students to take a copy of written asthma action plan to school/afterschool activities.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pregnancy&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Maintain asthma control through pregnancy&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Monitor asthma control during all prenatal visits; asthma worsens in one-third of women during pregnancy and improves in one-third; medications should be adjusted accordingly. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            It is safer to be treated with asthma medications than to have poorly controlled asthma. Maintaining lung function is important to ensure oxygen supply to the fetus. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Albuterol is the preferred SABA. ICS is the preferred long-term control medication (budesonide is preferred because more data are available on this medication during pregnancy). &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Surgery&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Reduce risks for complications during and after surgery.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess asthma control prior to surgery. If lung function is not well-controlled, provide medications to improve lung function. A short course of oral systemic corticosteroids may be necessary. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            For patients receiving oral systemic corticosteroids during 6 months prior to surgery and for selected patients on high dose ICS, give 100 mg hydrocortisone every 8 hours intravenously during the surgical period, and reduce the dose rapidly within 24 hours after surgery. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Managing Exacerbations&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Home Management&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Incorporate four components of care.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Include assessment and monitoring, patient education, environmental control, and medications.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Develop a written asthma action plan&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Instruct patients how to:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Recognize early signs, symptoms, and peak expiratory flow (PEF) measures that indicate worsening asthma. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Adjust medications (increase SABA and, in some cases, add oral systemic corticosteroids) and remove or withdraw from environmental factors contributing to the exacerbation. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Monitor response and seek medical care if there is serious deterioration or lack of response to treatment. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Management in the Urgent or Emergency Care Setting&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess severity. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Treat to relieve hypoxemia and airflow obstruction; reduce airway inflammation. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Monitor response. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Discharge with medication and patient education.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Treatment strategies include:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Assessing initial severity by lung function measures (for age &amp;ge;5 years) and symptom and functional assessment. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Supplemental oxygen. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Repetitive or continuous SABA. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Oral systemic corticosteroids. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Monitoring response with serial assessment of lung function measures, pulse oximetry, and symptoms. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Considering adjunctive treatments such as magnesium sulfate or heliox in severe exacerbations (e.g., forced expiratory volume in one second [FEV&lt;sub&gt;1&lt;/sub&gt;] or PEF &amp;lt;40 percent predicted) unresponsive to initial treatment. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Providing at discharge:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Medications: SABAs, oral systemic corticosteroids; consider initiating ICS. &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Referral for follow-up care. &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;An emergency department asthma discharge plan. &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Review of inhaler technique and, whenever possible, environmental control measures. &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;br /&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Classification of Asthma Severity&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; rowspan=&quot;3&quot; colspan=&quot;2&quot;&gt;Components of Severity&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;4&quot;&gt;Classification of Asthma Severity (&amp;ge;12 Years of Age)&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Intermittent&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Persistent&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Mild&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Severe&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Impairment&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Symptoms&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;2 days/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;2 days/week but not daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Throughout the day&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;4&quot;&gt;Normal FEV&lt;sub&gt;1&lt;/sub&gt;/FVC: &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            8-19 yr &amp;ndash;&lt;br /&gt;&#xD;&#xA;            &amp;ge;85% &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            20-39 yr &amp;ndash;&lt;br /&gt;&#xD;&#xA;            &amp;ge;80% &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            40-59 yr &amp;ndash;&lt;br /&gt;&#xD;&#xA;            &amp;ge;75% &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            60-80 yr &amp;ndash;&lt;br /&gt;&#xD;&#xA;            &amp;ge;70% &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Nighttime awakenings&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;2x/month&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3-4x/month&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;1x/week but not nightly&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Often 7x/week&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Short-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonist use for symptom control (not prevention of EIB)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;2 days/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;2 days/week but not daily, and not more than 1x on any day&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Several times per day&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Interference with normal activity&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Minor limitation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Some limitation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Extremely limited&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lung function&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Normal FEV&lt;sub&gt;1&lt;/sub&gt; between exacerbations &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt; &amp;gt;80% predicted &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt;/FVC normal &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt; &amp;gt;80% predicted &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt;/FVC normal &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt; &amp;gt;60% but &amp;lt;80% predicted &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt;/FVC reduced 5% &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;FEV&lt;sub&gt;1&lt;/sub&gt; &amp;lt;60% predicted&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Risk&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Exacerbations requiring oral systemic corticosteroids&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;0-1/year (see note)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&amp;ge;2/year (see note)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;4&quot;&gt;Consider severity and interval since last exacerbation. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Frequency and severity may fluctuate over time for patients in any severity category. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Relative annual risk of exacerbations may be related to FEV&lt;sub&gt;1&lt;/sub&gt;. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Recommended Step for Initiating Treatment&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            (See &quot;Stepwise Approach for Managing Asthma&quot; for treatment steps.) &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Step 1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Step 2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Step 3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Step 4 or 5 and consider short course of oral systemic corticosteroids&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;4&quot;&gt;In 2 to 6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;: EIB, exercise-induced bronchospasm; FEV&lt;sub&gt;1&lt;/sub&gt;, forced expiratory volume in one second; FVC, forced vital capacity&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Notes&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2 to 4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or intensive care unit [ICU] admission) indicate greater underlying disease severity. For treatment purposes, patients who had &amp;ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;br /&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Classification of Asthma Control&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; colspan=&quot;2&quot;&gt;Components of Control&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Classification of Asthma Control (&amp;ge;12 years of age)&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Well Controlled&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Not Well Controlled&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Poorly Controlled&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; rowspan=&quot;9&quot;&gt;Impairment&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Symptoms&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;2 days/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;2 days/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Throughout the day&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Nighttime awakenings&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;2x/month&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1-3x/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;ge;4x/week&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Interference with normal activity&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Some limitation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Extremely limited&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Short-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonist use for symptom control (not prevention of EIB)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;2 days/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;2 days/week&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Several times per day&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;FEV&lt;sub&gt;1&lt;/sub&gt; or peak flow&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;80% predicted/personal best&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;60%-80% predicted/personal best&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;60% predicted/personal best&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Validated questionnaires&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;ATAQ&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;0&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1-2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3-4&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;ACQ&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;0.75*&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;ge;1.5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;N/A&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;ACT&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;ge;20&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;16-19&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;15&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; rowspan=&quot;4&quot;&gt;Risk&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Exacerbations requiring oral systemic corticosteroids&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;0-1/year&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&amp;ge;2/year (see note)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Consider severity and interval since last exacerbation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Progressive loss of lung function&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Evaluation requires long-term follow-up care.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Treatment-related adverse effects&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Recommended Action for Treatment&lt;/strong&gt; &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            (See &quot;Stepwise Approach for Managing Asthma&quot; for treatment steps.)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Maintain current step. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Regular follow-up at every 1-6 months to maintain control. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider step down if well controlled for at least 3 months. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Step up 1 step. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Reevaluate in 2-6 weeks. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;For side effects, consider alternative treatment options. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Consider short course of oral systemic corticosteroids. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Step up 1-2 steps. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Reevaluate in 2 weeks. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;For side effects, consider alternative treatment options. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;: ACQ, Asthma Control Questionnaire&lt;sup&gt;&amp;copy;&lt;/sup&gt;; ACT, Asthma Control Test &lt;sup&gt;&amp;trade;&lt;/sup&gt;; ATAQ, Asthma Therapy Assessment Questionnaire&lt;sup&gt;&amp;copy;&lt;/sup&gt;; EIB, exercise-induced bronchospasm; FEV&lt;sub&gt;1&lt;/sub&gt;, forced expiratory volume in one second.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Minimal Important Difference: 1.0 for the ATAQ; 0.5 for the ACQ; not determined for the ACT.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*ACQ values of 0.76 to 1.4 are indeterminate regarding well-controlled asthma.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Notes&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;At present, there are inadequate data to correspond frequencies of exacerbation with different levels of asthma control. In general, more frequent and intense exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or intensive care unit [ICU] admission) indicate poorer disease control. For treatment purposes, patients who had &amp;ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Before Step Up in Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Review adherence to medication, inhaler technique, environmental control, and co-morbid conditions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;br /&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Step Up in Asthma Therapy&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Intermittent Asthma&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;5&quot;&gt;&lt;strong&gt;Persistent Asthma: Daily Medication&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Consult with asthma specialist if step 4 care or higher is required.&lt;br /&gt;&#xD;&#xA;            Consider consultation at step 3. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Step 6&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Step 5&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Preferred&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Step 4&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Preferred&lt;/em&gt;: &lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-dose ICS + LABA + oral corticosteroid&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Step 3&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Preferred&lt;/em&gt;: &lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-dose ICS + LABA&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;AND&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Step 2&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Preferred&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Medium-dose ICS + LABA&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;AND&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider omalizumab for patients who have allergies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Step 1&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Preferred&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low-dose ICS + LABA OR medium-dose ICS&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Alternative&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider omalizumab for patients who have allergies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Preferred&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low-dose ICS&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Alternative&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Medium-dose ICS + either LTRA, theophylline, or zileuton&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;SABA PRN&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;em&gt;Alternative&lt;/em&gt;:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low-dose ICS + either LTRA, theophylline, or zileuton&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cromolyn, LTRA, nedocromil, or theophylline&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;6&quot;&gt;&lt;strong&gt;Each step: Patient education, environmental control, and management of co-morbidities&lt;/strong&gt;.&lt;br /&gt;&#xD;&#xA;            Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see notes). &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;6&quot;&gt;Quick-Relief Medication for All Patients&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;SABA as needed for symptoms, intensity of treatment depends on severity of symptoms; up to 3 treatments at 20-minute intervals as needed. Short course of oral systemic corticosteroids may be needed. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Use of SABA &amp;gt;2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;: EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonist&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Notes&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Zileuton is a less desirable alternative due to limited studies as adjunctive therapy and the need to monitor liver function. Theophylline requires monitoring of serum concentration levels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In step 6, before oral corticosteroids are introduced, a trial of high-dose ICS + LABA + either LTRA, theophylline, or zileuton may be considered, although this approach has not been studied in clinical trials. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Step 1, 2, and 3 preferred therapies are based on the highest quality evidence; step 3 alternative therapy is based on high quality evidence for LTRA, medium quality evidence for theophylline and low quality evidence for zileuton. Step 4 preferred therapy and alternative therapy are based on medium quality evidence, as are Steps 5 and 6 preferred therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunotherapy for steps 2-4 is based on medium quality evidence for house-dust mites, animal dander, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians who administer immunotherapy or omalizumab should be prepared and equipped to identify and treat anaphylaxis that may occur. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classifying Severity of Asthma Exacerbations in the Urgent or Emergency Care Setting&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Patients are instructed to use quick-relief medications if symptoms occur or if peak expiratory flow (PEF) drops below 80 percent predicted or personal best. If PEF is 50 to 79 percent, the patient should monitor response to quick-relief medication carefully and consider contacting a clinician. If PEF is below 50 percent, immediate medical care is usually required. Refer to Figure 20 of the original guideline document for information on the likely clinical course of an exacerbation in the urgent or emergency care setting.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Second Visit: with Primary Care Physician MD/DO&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Determine response to empirical treatment or review diagnostic testing:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;If initial treatment is successful, continue with treatment recommendations provided above appropriate for the class of asthma with modifications based on efficacy and side effects. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Perform a spirometry or review the results of the peak flow diary. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Perform patient education at an appropriate level for the office visit. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If diagnostic testing provides a presumptive diagnosis, begin a therapeutic program. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If diagnostic testing does not provide a presumptive diagnosis, consider referral to a specialist. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Subsequent visits: with primary care physician MD/DO depend on results of the treatment program (see above); subsequent visits may also be for exacerbations of the asthma. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Since the NHLBI publication, several newer forms of treatment for asthma have been reported:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bronchial thermoplasty, utilizes heat to decrease the smooth muscle mass/function in the larger bronchial airways. It is still to be considered an experimental approach until more data can be presented. It has been used in individuals with severe asthma who fail traditional, aggressive forms of therapy. These individuals may not always be identified clinically or by physiologic parameters. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunomodulators:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lebrikizumab (an immunoglobulin G [IgG] 4 humanized monoclonal antibody to interleukin [IL]) 13. In one study, the use of this treatment resulted in greater levels of forced expiratory volume in one second (FEV&lt;sub&gt;1&lt;/sub&gt;) than could be achieved solely by standardized medications including inhaled corticosteroids. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Daclizumab (a humanized IgG1 monoclonal antibody against the IL-2R alpha chain [CD25] of activated lymphocytes) improved pulmonary function and asthma control in patients with moderate to severe chronic asthma inadequately controlled on ICS. The mechanism of action likely involves inhibition of proinflammatory cytokine generation by IL-2R blockade in activated T cells. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reslizumab (a monoclonal antibody to interleukin 5) in patients with eosinophilic asthma. This treatment reduced the levels of sputum eosinophils and significantly improved lung function in this subset of asthmatics. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dupilumab (a fully human monoclonal antibody to the alpha subunit of the interleukin-receptor). This treatment, in patients with persistent, moderate-to-severe asthma with elevated eosinophil levels, allowed for a reduction in LABA and inhaled glucocorticoids and diminished the frequency of acute exacerbations and levels of Th2-associated inflammatory markers. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticholinergic medications. While long used for the treatment of COPD, their use in the treatment of asthma has not been considered as important. Recent work suggests that there may be a place for this group of medications in the therapeutic armamentarium for the treatment of asthmatics. In a study of patients with poorly controlled asthma, despite the use of LABAs and ICS, the addition of a long-acting anticholinergic significantly increased the time to the first severe exacerbation and provided a modest increase in the FEV&lt;sub&gt;1&lt;/sub&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Additionally, while discussed in the 2007 NHLBI report, omalizumab was only &quot;considered&quot; for clinical use. Omalizumab is an anti-IgE monoclonal antibody that prevents the binding of IgE to high-affinity receptors on basophils and mast cells. Recent reports suggest that, in selected patients, it has the capacity to reduce the risk of hospitalization and emergency department (ED) visits in patients with uncontrolled severe asthma, even when on optimal control with LABAs and inhaled glucocorticoids.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Acute Exacerbations of Asthma&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the EPR3, acute exacerbations of asthma are classified into 4 severity levels based on the results of the clinical evaluation and the peak flow:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mild &amp;ndash; dyspnea with activities only with a PEF &amp;ge;70% predicted or personal best &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate &amp;ndash; dyspnea that limits normal activities with a PEF 40% to 69% predicted or personal best &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe &amp;ndash; dyspnea at rest; interferes with normal conversation with a PEF &amp;le;40% predicted or personal best &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe/life threatening &amp;ndash; too dyspneic to speak; perspiring with a PEF &amp;le;25% predicted or personal best &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Individuals with mild exacerbations can be cared for at home with short-acting beta-agonists with or without a short course of oral steroids. Individuals with moderate level exacerbations should be seen either in the office or the emergency room. Treatment is the same as in mild cases but it must be explained to the patient that the symptoms may last for 1 to 2 days. Severe cases require hospitalization, with more severe cases requiring admission to a critical care environment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The EPR3 monograph correctly states: &quot;Do not underestimate the severity of an exacerbation. Severe exacerbations can be life threatening and can occur in patients at any level of asthma severity &amp;ndash; i.e., intermittent, or mild, moderate, or severe persistent asthma.&quot; The report then describes risk factors for fatal outcomes that include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Previous severe exacerbation, for example, one that required an ICU admission and/or intubation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Two or more hospitalizations or more than 3 emergency room visits in the past year &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Difficulty perceiving airway obstruction or the severity of the worsening asthma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low socioeconomic status or inner-city residence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Illicit drug use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Major psychosocial problems or psychiatric disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Significant co-morbidities including cardiac or other pulmonary disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;During the comprehensive medical literature review, preference was given to high quality systematic reviews, meta-analyses, and clinical trials over the past ten years, plus existing nationally recognized treatment guidelines from the leading specialty societies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The heart of each Work Loss Data Institute guideline is the Procedure Summary (see the original guideline document), which provides a concise synopsis of effectiveness, if any, of each treatment method based on existing medical evidence. Each summary and subsequent recommendation is hyper-linked into the studies on which they are based, in abstract form, which have been ranked, highlighted, and indexed.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines unite evidence-based protocols for medical treatment with normative expectations for disability duration. They also bridge the interests of the many professional groups involved in diagnosing and treating asthma.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Adverse Effects of Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Concern has been raised over the long-term safety of &lt;em&gt;long-acting beta&lt;sub&gt;2&lt;/sub&gt; agonists (LABAs)&lt;/em&gt;. There is some justification to the concept that LABAs, used by themselves (monotherapy), as a substitute for inhaled corticosteroids, are associated with increased rates of serious exacerbations, hospitalizations, and mortality. This prompted the U.S. Food and Drug Administration (FDA) to issue a &quot;black-box warning,&quot; despite their clinical utility. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians who administer &lt;em&gt;immunotherapy&lt;/em&gt; or &lt;em&gt;omalizumab&lt;/em&gt; should be prepared and equipped to identify and treat anaphylaxis that may occur. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled corticosteroids (ICS) are recognized as first-line therapy in the management of asthma; however, their use may be limited by systemic and local side-effects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Treatment Planning section is not designed to be a rule, and therefore should not be used as a basis for Utilization Review. The Treatment Planning section outlines the most common pathways to recovery, but there is no single approach that is right for every patient and these protocols do not mention every treatment that may be recommended. See the Procedure Summaries in the original guideline document for complete lists of the various options that may be available, along with links to the medical evidence. The Procedure Summaries are the most important section of Official Disability Guidelines (ODG) Treatment, and that section, not the Treatment Planning section, should be used as a basis for Utilization Review.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Asthma. In: Pulmonary (acute &amp; chronic). Encinitas (CA): Work Loss Data Institute; 2013 Oct 29. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2009 Jan (revised 2013 Oct 29)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Work Loss Data Institute - For Profit Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Work Loss Data Institute&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Editor-in-Chief, Philip L. Denniston, Jr. and Senior Medical Editor, Charles W. Kennedy, Jr., MD, together pilot the group of approximately 80 members. See the ODG &lt;em&gt;Treatment in Workers Comp&lt;/em&gt; &lt;a href=&quot;http://www.worklossdata.com/editorial-advisory-board.html&quot; title=&quot;Work Loss Data Web site&quot;&gt;Editorial Advisory Board&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Chapter Lead&lt;/em&gt;: Stephen L. Demeter, MD, MPH&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;There are no conflicts of interest among the guideline development members.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Asthma. In: Pulmonary (acute &amp;amp; chronic). San Diego (CA): Work Loss Data Institute; 2009. p. 2-18.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available to subscribers from the &lt;a href=&quot;http://www.worklossdata.com/store/p1/ODG_Online_Access.html&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Work Loss Data Institute Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9992, Fax: 760-753-9995; &lt;a href=&quot;http://www.worklossdata.com&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;www.worklossdata.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Background &amp;amp; description. Available to subscribers from the &lt;a href=&quot;http://www.odg-twc.com/&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;Work Loss Data Institute (WLDI) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appendix B.&lt;em&gt; ODG Treatment in Workers' Comp&lt;/em&gt;. Methodology description using the AGREE instrument. 2014. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.worklossdata.com/uploads/2/4/1/6/24166932/odg_agree_2014.pdf&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;WLDI Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, self-training modules are available from the &lt;a href=&quot;http://www.worklossdata.com/training.html&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;WLDI Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ODG Mobile Pro is available to order from the &lt;a href=&quot;http://www.worklossdata.com/odg-mobile-pro.html&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;WLDI Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appendix C. &lt;em&gt;Official Disability Guidelines (ODG) Treatment in Workers' Comp&lt;/em&gt;. Patient information resources. 2008. Electronic copies: Available to subscribers from the &lt;a href=&quot;http://www.odg-twc.com/&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Work Loss Data Institute Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9992, Fax: 760-753-9995; &lt;a href=&quot;http://www.worklossdata.com&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;www.worklossdata.com&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on August 24, 2010. This summary was updated by ECRI Institute on November 12, 2010 following the U.S. Food and Drug Administration (FDA) advisory on Afluria (influenza virus vaccine). This NGC summary was updated by ECRI Institute on February 19, 2014. This summary was updated by ECRI Institute on November 14, 2014 following the U.S. Food and Drug Administration advisory on Xolair (omalizumab).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
